Interleukin 35 (IL-35) is a potent immunosuppressive cytokine, consisting of an Epstein-Barr virus-induced gene 3 (EBI3) subunit and a p35 subunit. IL-35 is mainly produced by regulatory T and regulatory B cells, and plays a crucial role in the development and prevention of infectious and autoimmune diseases. However, the effect of IL-35 in malignant disease is not well understood. In this study, we demonstrated that breast cancer cells (BCCs) also expressed and secreted IL-35 and higher level of IL-35 in BCCs was closely associated with poor prognosis of patients and was an independent unfavorable prognostic factor for breast cancer. Subsequent study revealed that BCC-derived IL-35 inhibited conventional T (T conv ) cell proliferation and further induced suppressed T conv cells into IL-35-producing induced regulatory T (iTr35) cells. Furthermore, BCC-derived IL-35 promoted the secretion of inhibitory cytokine IL-10 and obviously decreased the secretion of Th1-type cytokine IFN-γ and Th17-type cytokine IL-17 in T conv cells. Meanwhile, the expression of inhibitory receptor CD73 was also elevated on the surface of T conv cells following the BCCs' supernatant treatment. Mechanistically, BCC-derived IL-35 exhausted T conv cells and induced iTr35 by activating transcription factor STAT1/STAT3. Hence, our results indicate functions of BCC-derived IL-35 in promoting tumor progression through proliferation inhibition of tumor-infiltrating T conv cells and induction of iTr35 cells in tumor microenvironment. This study highlights that IL-35 produced by BCCs are a potential therapeutic target for breast cancer.
Introduction
Breast cancer is the most frequently diagnosed cancer and the second leading cause of cancer-related deaths among Chinese women (1) . In spite of improvements in surgical and pharmaceutical strategies, there remains high rates of recurrence and metastases of breast cancer and a major cause of tumor progression is immune suppression in cancer (2, 3) .
Regulatory T cells (Tregs), a unique subset of CD4 + T cells, have been found to play key roles in maintaining suppressive tumor microenvironment and thus contribute to cancer progression. Although Tregs normally comprise only ~4% of CD4 + T cells in adult peripheral blood, they can make up as much as 20-30% of the total CD4 + T cell population in tumor microenvironment (4, 5) . Increased numbers of Tregs are correlated with poor prognosis in various types of cancers including breast cancer (6) . Two subsets of Tregs have been confirmed: naturally occurring Tregs (nTregs) that occur and develop in the thymus and induced Tregs (iTregs) that generate from natural conventional T (T conv ) cells in the periphery. According to the cytokines that induced them, three types of iTregs have been described: iTr-TGF-β, iTr-IL-10 and iTr-IL-35 (iTr35). Immunosuppressive cytokine interleukin-35 (IL-35) induces the conversion of T conv cells into IL-35-producing regulatory T (iTr35) cells.
IL-35, a novel member of IL-12 family, exists as a heterodimer of EBI3 (IL-27β) and p35 (IL-12a) (7) . IL-35 is mainly produced by Tregs and regulatory B cells and contributes to the immune suppression function of these cells (8, 9) . Recent studies have found that IL-35 is also expressed in some types of cancer cells, such as pancreatic cancer, colon cancer and hepatocellular carcinoma (10) (11) (12) . In vivo studies have shown that IL-35 neutralization limits tumor growth in multiple mouse models of human cancer (13) . Therefore, IL-35 has emerged as a new biomarker and a potential therapeutic target for cancer. In this study, we demonstrated that breast cancer cells (BCCs) expressed and secreted IL-35, and BCC-derived IL-35 was capable of inhibiting the proliferation of T conv cells and converting them into iTr35 cells, which contributed to the progression of breast cancer and poor prognosis of patients.
Materials and methods

Cell lines and cell culture
Human breast cancer cell lines MDA-MB-231 (231), MCF-7, SKBR-3 and T47D were obtained from the American Type Culture Collection. HEK293T cell line was obtained from Chinese Academy of Sciences Cell Bank. All cells were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA,) medium containing 10% fetal bovine serum (Gibco, Auckland, New Zealand) in a humidified atmosphere of 5% CO 2 at 37°C. All cell lines were cytogenetically tested and authenticated before the cells were frozen. Each vial of frozen cells was thawed and maintained for a maximum of 12 weeks.
Breast cancer patients
Eighty-six unrelated Chinese women with breast cancer who underwent lumpectomy or mastectomy were from the Second Hospital of Shandong University and Dongying People's Hospital of Shandong Province, excluding patients receiving neoadjuvant chemotherapy or neoadjuvant radiotherapy. Clinicopathological characteristics included age of onset, histological grade, pathological tumor, node, metastases (TNM) stage, the status of estrogen receptor, progesterone receptor (PR), human epithelial growth factor receptor 2, lymph node involvement, progression-free survival and overall survival. Human study was approved by the Human Investigation Committee of the Second Hospital of Shandong University and Dongying People's Hospital of Shandong Province, and informed consent was obtained from each study participant.
Isolation of T conv cells
Human peripheral blood mononuclear cells from leukocyte-enriched buffy coats were separated on a Ficoll (Sigma) gradient and T conv cells (CD4 + CD25 − CD45RO − ) were purified by negative selection using a Naive CD4 + T Cell Isolation Kit (Miltenyi Biotec, Germany). The purity was >97% as confirmed by flow cytometry.
Immunohistochemistry
The immunohistochemistry (IHC) was used to detect Epstein-Barr virusinduced gene 3 (EBI3) and p35 expression in breast cancer tissues. In brief, the paraffin-embedded tissue sections were deparaffinized followed by microwave treatment in ethylenediaminetetraacetic acid solution for 15 min. After being treated with 3% hydrogen peroxide and blocked with 10% goat serum, the consecutive tissue sections were probed with primary antibodies, including anti-EBI3 (5 μg/ml; Novus Biologicals) and anti-p35 (5 μg/ml; R&D Systems, Minneapolis, MN), at 4ºC overnight. Then, tissue sections were incubated with the biotinylated secondary antibody, followed by performing the chromogenic reaction using a DAB Substrate Kit. The images were captured using an Olympus microscope.
All the slides were independently analyzed by two pathologists. The intensity of the staining was evaluated using the following criteria: 0, negative; 1, low; 2, medium and 3, high. The extent of staining was scored by using the following criteria: 0, 0% stained; 1, 1-25% stained; 2, 26-50% stained and 3, 51-100% stained. Five random fields (×20 magnification) were evaluated under a light microscope. The final scores were calculated by multiplying intensity and extent scores, and the samples were divided into four grades: 0, negative (−); 1-2, low staining (+); 3-5, medium staining (++) and 6-9, high staining (+++). The following criteria were used to quantify the expression levels of IL-35 in breast cancer tissues: high expression, both EBI3 and P35 were scored as ++/+++; low expression, other than high expression.
Induction of iTr35 cells
T conv cells were activated with CD3/CD28 T cell activator (12 μl/ml; STEMCELL Technologies, Canada) and cultured in RPMI 1640 medium containing 10% fetal bovine serum and 100 U/ml rhIL-2 (PeproTech). For induction of iTr35 cells, rhIL-35 (50 or 100 ng/ml; PeproTech) or culture supernatants (SN) of 231 or MCF-7 at a volume 30% of the total culture volume were added to T cell culture system for 5 days.
Cell Counting Kit-8 assay
The direct effect of BCC-derived IL-35 on T conv cells growth was measured by Cell Counting Kit-8 (CCK-8) assay. Briefly, T conv cells were seeded in triplicate into 96-well plates at 1 × 10 5 cells per well with rhIL-35, or BCCs' SN in the presence of a neutralizing anti-IL35 monoclonal antibody (mAb) (10 μg/ml, clone 27537; R&D Systems) or not for 5 days and the fresh conditional medium was added every 2 days (14) . After treatment, 10% of CCK-8 buffer (Dojindo, Kumamoto, Japan) was added to culture medium for the final 2 h at 37°C until visible color conversion occurred. The absorbance value was detected at 450 nm wavelength by a Microplate Reader (Bio-Rad, Hercules, CA). Results were representative of three independent experiments.
RNA extraction and real-time quantitative reverse transcription PCR
Total RNA was extracted from the BCCs or T cells with TRIzol reagent (Invitrogen) in accordance with the manufacturer's protocol. Equal amounts of total RNA from each sample were then reverse-transcribed into cDNA using a Revert Ace kit (Toyobo, 538100). The following sequencespecific primers were used for PCR amplification: (i) the internal control GAPDH gene: forward, 5′-GGT GGT CTC CTC TGA CTT CAA CAG-3′, reverse, 5′-GTT GTT GTA GCC AAA TTC GTT GT-3′; (ii) ebi3 gene: forward, 5′-GCA GCA GAC GCC AAC GT-3′, reverse, 5′-CCA TGG AGA ACA GCT GGA CAT-3′; (iii) p35 gene: forward, 5′-CCT TCA CCA CTC CCA AAA C-3′, reverse, 5′-TGT CTG GCC TTC TGG AGC AT-3′. The primers used in Figure 1I and J were as follows: (i) ebi3 gene: forward, 5′-TTC ATT GCC ACG TAC AGG CT-3′, reverse, 5′-GGA TGA GGA CGT GGC TTC AA-3′; (ii) p35 gene: forward, 5′-TTC CCA TGC CTT CAC CAC TC-3′, reverse, 5′-ACA GGG CCA TCA TAA AAG AGG T-3′. Amplification cycle conditions were set up as follows: 95°C for 60 s, followed by 40 cycles of 94°C for 5 s, 60°C for 10 s and 72°C for 15 s, with final extension of 45 s at 72°C. Data were normalized to the internal control and relative expression levels were evaluated using the 2 −ΔΔCt method. All experiments were conducted in triplicate.
Flow cytometry and intracellular staining
For cell-surface markers, T cells were harvested and incubated with antihuman CD4-FITC, CD73-PE, LAG3-PE, CTLA-4-PE or appropriate isotype controls (eBioscience, San Diego, CA) for 30 min at 4°C. For intracellular cytokine detection, cells were stimulated with 1× cell stimulation cocktail (eBioscience) for 10-12 h and were fixed and permeabilized using Cytofix/ Cytoperm™ Fixation/Permeabilization Solution Kit (eBiosciences). The harvested cells were stained with FITC-labeled anti-CD4 and then with PE-labeled anti-EBI3, or isotype-matched control antibody (eBioscience). Finally, the stained cells were analyzed by flow cytometry and data analysis was done using FCS Express, V3 (De Novo).
Abbreviations
Cytokine measurement
For IL-35 level measurement, SN from BCCs were harvested and determined using human IL-35 enzyme-linked immunosorbent assay (ELISA) kits (sensitivity: 15.6 pg/ml; Cusabio, China). For cytokine analysis of T conv culture system, T conv cells were cultured for 5 d after stimulation with rhIL-35 or BCCs'
SN. Cytokine production of IL-1β, IL-4, IL-6, IL-10, IL-12p70, IL-17a, TNF-α and IFN-γ was simultaneously determined by the commercially available Human High Sensitivity Panel (eBioscience). The assay was performed according to the manufacturer's instructions and each sample was run in duplicate.
Western blotting
The harvested cells were washed with phosphate-buffered saline and suspended in radioimmunoprecipitation lysis buffer. The protein in MDA-MB-231 cells were detected. Data are representative of three independent experiments and presented as mean ± SEM of three replicates (F-K). TILs, tumorinfiltrating lymphocytes; BCCs, breast cancer cells. Scale bars, 100 μm. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
concentration was evaluated using the BCA Protein Assay (Beyotime). An aliquot of total protein was separated by 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis and was further electrotransferred onto polyvinylidene difluoride membranes. After being blocked using 5% non-fat dried milk for 1 h at room temperature, the membranes were probed with anti-EBI3 (1:500; Santa Cruz Biotechnology, Santa Cruz, CA), anti-p35(1 μg/ml; R&D Systems), anti-phospho-STAT1(Tyr701) (1:1000), anti-STAT1 (1:1000), anti-phospho-STAT3 (1:1000), anti-STAT3 (1:1000), anti-phospho-STAT4(Tyr693) (1:1000), anti-STAT4 (1:1000) and anti-GAPDH (1:1000) (Cell Signal Technology, Beverly, MA) antibodies overnight at 4°C, followed by treatment with horseradish-peroxidase-conjugated secondary antibodies. The signals of labeled proteins were detected by enhanced chemiluminescence (Life Technologies, Carlsbad, CA).
CRISPR/Cas9 targeting and generation of lentiviral constructs
Single guide RNAs (sgRNA) targeted to ebi3 and p35, respectively, were designed and then cloned into pLenti CRISPR V2 (Hu6-sgRNA-EF1a-CAS9-puro) vectors (LncBio Shanghai, China). All plasmids were sequenced to confirm successful ligation (Supplementary Figure 2 , available at Carcinogenesis Online). The following sgRNA sequences were utilized: (i) sg ebi3#1: 5′-GGCGGTGACATTGAGCACGTAGG-3′, (ii) sg ebi3#2:
The HEK293T cells were maintained as recommended by the manufacturer in 100 mm dishes. For each transfection, 4 µg CRISPR/Cas9 vector carrying the construct of interest, 4 µg psPAX2 envelope plasmid and 2 µg pMD2.G packaging plasmids were used. The transfection was carried out using jetPRIME (Polyplus, New York) following the manufacturer's recommendations. Virus was harvested at 48 h post-transfection.
Generation of recombinant stable cell lines
To knock out gene expression of ebi3 or p35, MDA-MB-231 cells were transducted with CRISPR/Cas9 virus for 24 h using 8 μg/ml polybrene (LncBio). Two days after transduction, selection of recombinant cells was performed in the presence of 2.0 µg/ml puromycin (Solarbio, Beijing, China).
Statistical analysis
IHC scores of different subgroups were compared by chi-square test. Kaplan-Meier curves were analyzed for relevant variables. The log-rank test was used to analyze the differences in survival time among the patient subgroups. The Cox's proportional hazard regression model was used to evaluate risk factors associated with the prognoses. Pearson's correlation coefficient (r value) was calculated assuming linear relationship between variables. The data represent the mean values ± the standard error of mean. Comparison between groups was performed using unpaired Student's t-test with GraphPad Prism5 software. A P ≤ 0.05 (two-sided) was considered statistically significant.
Results
IL-35 was expressed in breast cancer tissues and was positively associated with poor prognosis
We first examined the expression of IL-35 in breast cancer tissues. Since IL-35 is a heterodimeric protein, which is composed of EBI3 and p35 subunits, we detected the expression of EBI3 and p35 using serial sections by IHC. As shown in Figure 1A , EBI3 and p35 were co-expressed in the cytoplasm of most cancer cells and part of tumor-infiltrating lymphocytes. Furthermore, the expression of EBI3 and p35 was correlated strongly (r = 0.77, P < 0.0001) ( Figure 1B and C) . These results demonstrated that BCCs expressed IL-35.
Subsequently, we performed the analysis of association between the expression of IL-35 and clinicopathological information in 86 patients with breast cancer. According to the IHC scores of EBI3 and p35, we stratified breast cancer samples into two groups: 'high IL-35' and 'low IL-35'. As shown in Table 1 , higher level of IL-35 was significantly associated with poor differentiation, negative estrogen receptor status, negative PR status and positive Her-2 status. The survival data from 86 patients with breast cancer were also assessed in this study. The results showed that IL-35 level was significantly correlated with the survival rate of patients. Both the overall survival rate and progression-free survival rate of patients with low IL-35 expression were better than those with high IL-35 expression (P = 0.0009 and 0.0008) (Figure 1D and E) . The multivariate Cox's regression analysis revealed that IL-35 expression was an independent unfavorable prognostic factor for breast cancer (hazards ratio, 3.779; 95% confidence interval, 1.046-13.653; P = 0.043; Table 2 ).
BCCs expressed and secreted IL-35
To screen appropriate breast cancer cell lines for in vitro study, we investigated the expression and secretion of IL-35 in four breast cancer cell lines. The two subunits of IL-35 were detectable in all of four cell lines and the higher IL-35 level was observed in 231 and MCF-7 cells, which were verified by real-time reversetranscription PCR ( Figure 1F and G) and ELISA ( Figure 1H ). The specificity of the IL-35 ELISA was demonstrated using 231 cells in which the ebi3 or p35 gene was inactivated using the CRISPR/ CAS9 system ( Figure 1I-K) . On the basis of these results, 231 and MCF-7 cell lines were chosen for subsequent experiments. According to 7th edition of UICC TNM classification of malignant tumors.
BCCs' SN inhibited the proliferation of T conv cells in IL-35-dependent manner
IL-35 secreted by Tregs suppressed the proliferation of T conv cells (14). To evaluate whether IL-35 produced by BCCs also had
Bold values in italics are statistically significant. *P ≤ 0.05, **P ≤ 0.01. similar function, we tested the inhibitory effect of BCCs' SN on T conv cell proliferation using neutralizing IL-35 mAb and CCK-8 assay. As shown in Figure 2A , both SN from 231 and MCF-7 cells markedly suppressed the proliferation of T conv cells and IL-35-blocking could partially reverse these effects. Therefore, BCCs' SN inhibited T conv cell proliferation in an IL-35-dependent manner.
BCC-derived IL-35 induced iTr35 cells
Given our finding that IL-35 secreted by BCCs suppressed the proliferation of T conv cells strongly, we next sought to determine whether BCC-derived IL-35 could convert T conv cells to iTr35 cells. We monitored that, compared with control, T conv cells activated with anti-CD3/CD28 in the presence of BCCs' SN simultaneously upregulated the expression of IL-35 at both mRNA and protein levels ( Figure 2B-D) . Single-cell analysis by intracellular cytokine staining also suggested that treatment with BCCs' SN or rhIL-35 induced the expression of IL-35 in T conv cells ( Figure 2E ). These data confirmed that BCC-derived IL-35 converted T conv cells into suppressive iTr35 cells.
Cytokine secretion profiles of T conv cells treated by BCCs' SN
Next, we analyzed the cytokine secretion profiles of T conv cells treated with BCCs' SN, including IL-1β, IL-4, IL-6, IL-10, IL-12p70, IL-17a, TNF-α and IFN-γ ( Figure 3AH ). Secretion of IL-10 and IL-12p70 was obviously upregulated, whereas the secretion of Th1-type cytokine IFN-γ and Th17-type cytokine IL-17 was markedly depressed in both IL-35 groups and BCCs' SN-treated groups ( Figure 3A-D) . Furthermore, compared with BCCs' SN-treated T conv cells, the addition of IL-35 functional mAb reversed these effects. In addition, we also found that the levels of IL-1β and IL-4 were significantly increased in BCCs' SN-treated groups compared with those in the control group, but these changes were uncorrelated with IL-35 treatment ( Figure 3E and F). 
Inhibitory receptor expression on T conv cells treated by BCCs' SN
It has been reported that nTregs express surface inhibitory receptors (IRs), such as CD73, LAG3 and CTLA-4, which contribute to the suppressive function of Tregs themselves (15) (16) (17) . In this study, we also detected the surface expression of IRs on T conv cells treated by BCCs' SN. As shown in Figure 3I , the percentage of CD73 + T conv cells is upregulated in BCCs' SN-treated groups. However, BCCs' SN treatment had no effect in the induction of LAG3 and CTLA-4, which had been described as mediators of nTregs suppression.
BCC-derived IL-35 signaled through STAT1 and STAT3
On the basis of the earlier results, we further explored the molecular mechanisms involved in T conv cell proliferation inhibition and iTr35 cell induction by BCC-derived IL-35. The STAT protein family played a pivotal role during cellular differentiation and immunoregulation (18) . Published reports showed that both IL-27 and IL-12, which shared subunits with IL-35, induced the phosphorylation of STAT1, STAT3 and STAT4 (19) . The treatment of mouse T conv cells with IL-35 resulted in intracellular phosphorylation of STAT1 and STAT4 (20) . In this study, we examined Figure 4A , increased p-STAT1 and p-STAT3 expressions were observed in IL-35-treated groups and BCCs' SN-treated groups compared with control T conv cells, and the addition of IL-35-blocking mAb in BCCs' SN-treated groups could partially reverse these effects. Moreover, the effect of BCCs' SN groups was more pronounced than that of rhIL-35 groups ( Figure 4A) . However, the expression of p-STAT4 was not detectable in all groups ( Figure 4A ). These indicated that BCC-derived IL-35 inhibited T conv cell proliferation and converted T conv cells into iTr35 cells through activation of STAT1/STAT3 pathway.
Discussion
Tumor progression is a multistep process depending on both tumor behavior and the immune function of the host. Immune function is generally compromised in most patients with cancer (21) (22) (23) . It is reported that there are increased numbers of functionally suppressive Tregs in the peripheral blood and tumor microenvironment of patients with cancer, including breast cancer, colorectal cancer and lung cancer (24) (25) (26) (4, 5) . In this study, we found that BCCs also expressed and secreted IL-35 in addition to nTregs and iTr35 cells. Furthermore, elevated IL-35 expression in BCCs was significantly correlated with more aggressive tumor phenotypes, including poor differentiation, PR-negative expression and estrogen receptor-negative expression. We also assessed the prognostic value of IL-35 by a long-term follow-up investigation and found that BCC-derived IL-35 was an independent unfavorable prognostic factor for breast cancer.
As an inhibitory cytokine, IL-35 has three known biological functions: suppression of T-cell proliferation, the conversion of T conv cells into iTr35 cells and downregulation of Th17 cell development and differentiation (14, 27) . To determine whether Another important finding of this study was that BCCderived IL-35 treatment led to the change of cytokine production in T conv cells. A previous study showed that both T conv cells and IL-35-treated T conv cells had similar production of cytokines in a mouse model (14) . However, in contrast to the previous report, our study demonstrated that BCC-derived IL-35 induced higher levels of IL-10 and IL-12 (IL-12p70) secretion and lower levels of IFN-γ and IL-17a secretion in T conv cells, compared with control group in humans. It was known that IL-12 shared p35 subunit with IL-35; therefore, we speculated that evaluated IL-12p70 level might be attributed to high level of IL-35 that was secreted by BCCs and iTr35 cells induced by BCC-derived IL-35. On the other hand, increased secretion of IL-10 could promote T conv cells to differentiate into inhibitory iTr-IL-10 cells and suppress the function of Th1 and Th17 cells (28) . And it was further confirmed by our results that Th1-type cytokine IFN-γ and Th17 cytokine IL-17a were dramatically decreased in both rhIL-35 treatment group and BCC-derived IL-35 treatment group. IFN-γ and IL-17a played important antitumor roles by inducing the differentiation of Th1 and Th17 cells, respectively, and inhibiting Th2 formation (29, 30) . The earlier results proved that BCC-derived IL-35 not only directly suppressed the proliferation of Th1 and Th17 cells, but also indirectly inhibited their functions by promoting the secretion of IL-10 in T cells, which further clearly pointed out the role of BCC-derived IL-35 in maintaining suppressive tumor microenvironment. However, IL-35 mAb treatment rebounded IFN-γ and IL-17a production of T conv cells and brought about the recovery of BCC-derived IL-35-induced proliferation inhibition of T conv cells.
It has been reported that surface IRs LAG3, CD73 and CTLA-4 mediated the immunosuppression function of nTregs (13, 31, 32) . In this study, we also tested whether these membrane IRs changed in rhIL-35-treated and BCCs' SN-treated T conv cells. The results showed that BCCs' SN facilitated CD73 expression of T conv cells. In general, Tregs preferentially express CD73, which converts adenosine monophosphate to highly immunosuppressive adenosine and enhances suppressive function of Tregs (33) . Therefore, elevated CD73 may promote inhibitory function of BCCs' SN-induced T conv cells. Nevertheless, no difference on the surface expression of LAG3 and CTLA-4 was observed between rhIL-35-treated or BCCs' SN-treated T conv cells and control group. This result was supported by the work of Collison LW that multiinhibitory receptors were at same level in both T conv cells and iTr35 cells (14) .
Lastly, we explored the molecular mechanisms involved in the induction of iTr35 cells by BCC-derived IL-35. As IL-35 receptor uses IL-12Rβ2 and gp130, it is possible that signaling is mediated via the STAT family of transcription factors (20) . In fact, previous studies from mouse models revealed that IL-35 induced the transcription of STAT1 and STAT4 in T conv cells and STAT1 and STAT3 in B cells (8, 20) . In humans, only STAT1 and STAT3 were activated by IL-35 expressed by tumor-infiltrating Tregs in colorectal cancer during the induction of iTr35 cells (24) . Our previous results confirmed that IL-35 treatment of human monocyte-derived dendritic cells resulted in phosphorylation of STAT1 and STAT3 (34) . These data suggested the possibility that IL-35 might use different signaling components in different species or different types of cells, or different results derived from different sources of IL-35. In this study, we demonstrated that STAT1 and STAT3 but not STAT4 were involved in the induction of iTr35 cells by BCC-derived IL-35. STAT1 is a well-known transcription factor, which plays a critical role in the generation of immunosuppressive function of Tregs and regulatory B cells (8, 35, 36) . On the other hand, activation of STAT3 is important for enhancing human iTreg phenotype and function (37) . Therefore, the activation of both STAT1 and STAT3 led to the phenotypic differentiation and functional performance of iTr35 cells induced by BCC-derived IL-35.
In conclusion, BCCs expressed and secreted IL-35. BCCderived IL-35 inhibited T conv cell proliferation and further converted suppressed T conv cells into iTr35 cells via activation of STAT1/STAT3 signaling pathway. This might constitute a positive feedback loop: BCC-derived IL-35 inhibited the proliferation of tumor-infiltrating lymphocytes and further induced them into iTr35 cells, which subsequently produced more IL-35 and iTr35 cells in tumor microenvironment ( Figure 4B ). By this means, BCCs promoted their own development and progression and led to the poor prognosis of breast cancer patients. Our study provided evidence for a novel tumor-evading mechanism in breast cancer and suggested that IL-35 might be a potential therapeutic target for the treatment of breast cancer.
